Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 23;8(2):131.
doi: 10.3390/jcm8020131.

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer

Affiliations

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer

Paola Ulivi et al. J Clin Med. .

Abstract

Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related death worldwide, with a low 5-year survival rate even in fully resected early-stage disease. Novel biomarkers to identify patients at higher risk of relapse are needed. We studied the prognostic value of 84 circulating microRNAs (miRNAs) in 182 patients with resected early-stage NSCLC (99 adenocarcinoma (ADC), 83 squamous cell carcinoma (SCC)) from whom peripheral blood samples were collected pre-surgery. miRNA expression was analyzed in relation to disease-free survival (DFS) and overall survival (OS). In univariable analyses, five miRNAs (miR-26a-5p, miR-126-3p, miR-130b-3p, miR-205-5p, and miR-21-5p) were significantly associated with DFS in SCC, and four (miR-130b-3p, miR-26a-5p, miR-126-3p, and miR-205-5p) remained significantly associated with OS. In ADC, miR-222-3p, miR-22-3p, and mir-93-5p were significantly associated with DFS, miR-22-3p remaining significant for OS. Given the high-dimensionality of the dataset, multivariable models were obtained using a regularized Cox regression including all miRNAs and clinical covariates. After adjustment for disease stage, only miR-126-3p showed an independent prognostic role, with higher values associated with longer DFS in SCC patients. With regard to ADC and OS, no miRNA remained significant in multivariable analysis. Further investigation into the role of miR-126 as a prognostic marker in early-stage NSCLC is warranted.

Keywords: early-stage NSCLC; miRNAs; plasma; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
DFS Kaplan–Meier curves for SCC patients. Disease-free survival risk table and leave-one-out cross-validated Kaplan–Meier curves for SCC high (red solid line) and low risk (green dotted line) patients groups along with their 95% confidence interval (accordingly shaded areas); permutated log-rank p-value for the hypothesis testing of equality of curves between groups is also reported.
Figure 2
Figure 2
ROC curves for SCC patients. Cross-validated time-dependent ROC curves for the combined (cyan solid line) and stage-only (dashed blue line) models in SCC patients; bisector gray line identifies a purely random discrimination.

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Chee K.G., Nguyen D.V., Brown M., Gandara D.R., Wun T., Lara P.N., Jr. Positron emission tomography and improved survival in patients with lung cancer: The Will Rogers phenomenon revisited. Arch. Intern. Med. 2008;168:1541–1549. doi: 10.1001/archinte.168.14.1541. - DOI - PubMed
    1. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., Cormier Y., Goss G., Inculet R., Vallieres E., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005;352:2589–2597. doi: 10.1056/NEJMoa043623. - DOI - PubMed
    1. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer. 2005;5:845–856. doi: 10.1038/nrc1739. - DOI - PubMed
    1. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer. 2006;6:857–866. doi: 10.1038/nrc1997. - DOI - PubMed